Enfortumab Vedotin Yields High Response Rate in Advanced Urothelial Cancer
The investigators said the data justify and support the submission of enfortumab vedotin for consideration under FDA’s accelerated approval pathway.
Next post in Upper tract urothelial carcinoma
